Sementis
Sydney, Australia· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Sementis leverages a novel vaccinia‑based platform to create curative allergy vaccines that retrain immune memory.
ImmunologyAllergy
Technology Platform
The Sementis Copenhagen Vector (SCV) is a fourth‑generation, replication‑deficient vaccinia viral vector with a large genetic capacity and plug‑and‑play capability, enabling rapid development of multi‑allergen therapeutic vaccines.
Opportunities
A curative, short‑course allergy vaccine could capture a large unmet market and the SCV platform can be extended to multiple allergens and other immunological indications.
Risk Factors
Regulatory approval of a novel viral vector, safety concerns, and competition from established allergen immunotherapy approaches.
Competitive Landscape
Few companies focus on curative allergy vaccines; Sementis differentiates through its SCV platform that delivers durable immune memory and blocking antibodies, unlike conventional desensitization or passive antibody therapies.